ESTRO PT 2018

NRG:

Prostate: RTOG-0938. Phase II trial with hypofractionated RT for favorable risk prostate cancer . It randomized between 7.25 Gy in 5 fractions versus 4.3 Gy in 12 fractions. Stage T1-T2 disease. Study closed – reached accrual. Thus far, although protons were allowed, (almost) no proton patients entered. Liver: RTOG-1112 , open and permitting protons. Randomized phase III study of Sorafenib alone versus SBRT followed by Sorafenib in hepatocellular CA. Intention is to give 50 Gy in 5 fractions. Total dose prescription dependent on the mean liver dose tolerance. Prescription dose to be lowered until a level that permits mean liver dose OAR to be met. Open NRG-G1003 : A Phase III Randomized Trial of Protons versus Photons for Hepatocellular Carcinoma Endpoint: Overall Survival Unresectable or locally recurrent Open to Accrual. Target 187 patients